

Development of a food compositional database for the estimation of dietary intake of phyto-oestrogens in a group of postmenopausal women previously treated for breast cancer and validation with urinary excretion

Don B. Clarke^{1*}, Antony S. Lloyd², Judy M. Lawrence³, Jonathan E. Brown⁴, Lesley Storey⁵, Monique Raats⁵, Richard M. Rainsbury⁶, D. J. Culliford⁷, Victoria A. Bailey-Horne^{2,8} and Barbara M. Parry⁶

¹*Emergency Response and Recovery Programme, Food and Environment Research Agency, Sand Hutton, York YO41 1LZ, UK*

²*Food and Environment Safety Programme, Food and Environment Research Agency, Sand Hutton, York YO41 1LZ, UK*

³*European Institute of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK*

⁴*Division of Nutritional Sciences, University of Surrey, Guildford GU2 7XH, UK*

⁵*Food, Consumer Behaviour and Health Research Centre, University of Surrey, Guildford GU2 7XH, UK*

⁶*WINS Research Team, Winchester and Andover Breast Unit, Royal Hampshire County Hospital, Winchester SO22 5DG, UK*

⁷*RDSU, University of Southampton, Southampton SO16 6YD, UK*

⁸*Department of Chemistry, University of York, Heslington, York YO10 5DD, UK*

(Submitted 21 May 2012 – Final revision received 15 August 2012 – Accepted 17 August 2012)

Abstract

The scientific literature contains evidence suggesting that women who have been treated for breast cancer may, as a result of their diagnosis, increase their phyto-oestrogen (PE) intake. In the present paper, we describe the creation of a dietary analysis database (based on Dietplan6) for the determination of dietary intakes of specific PE (daidzein, genistein, glycitein, formononetin, biochanin A, coumestrol, matairesinol and secoisolariciresinol), in a group of women previously diagnosed and treated for postmenopausal breast cancer. The design of the database, data evaluation criteria, literature data entry for 551 foods and primary analysis by LC–MS/MS of an additional thirty-four foods for which there were no published data are described. The dietary intake of 316 women previously treated for postmenopausal breast cancer informed the identification of potential food and beverage sources of PE and the bespoke dietary analysis database was created to, ultimately, quantify their PE intake. In order that PE exposure could be comprehensively described, fifty-four of the 316 subjects completed a 24 h urine collection, and their urinary excretion results allowed for the description of exposure to include those identified as ‘equol producers’.

Key words: Phyto-oestrogens: Isoflavones: Dietary analysis databases: Breast cancer

Phyto-oestrogens (PE) are bioactive plant constituents capable of inducing a wide range of oestrogenic effects in humans⁽¹⁾. They have been reported to possess antioxidant activities, anti-inflammatory properties, vasodilatory effects and may help in the alleviation of menopausal symptoms⁽²⁾. There is some evidence of their effect on reducing the age-related decline in bone density⁽³⁾, and in the reduction of the incidence of CVD and hormone-dependent cancers. Individual studies continue to report reduced cancer risk with increasing PE intake⁽⁴⁾, while the conclusions from meta-analysis are more restrained, suggesting both soya and lignan intake may be associated with small reductions in breast cancer risk^(5–9). Consequently, the question of whether or not PE

are beneficial or harmful to human health remains unresolved. The answer is likely to be complex and may depend on age at exposure to PE, health status and even the presence or absence of specific gut microflora. Clarity on this issue is needed because global consumption of PE is rapidly increasing⁽¹⁰⁾. Evidence indicates that women who have been treated for breast cancer may, as a result of their diagnosis, increase their PE intake, perhaps as an alternative to conventional hormone replacement therapy, or because of a belief that PE may help them avoid a recurrence of the disease^(11–13). At this stage, there is no recommended intake for PE and there are concerns about the safety of a high PE intake⁽¹⁴⁾, especially in subgroups of the population such as breast cancer patients.

Abbreviations: Daid, daidzein; Equ, equol; PABA, *para*-aminobenzoic acid; PE, phyto-oestrogen; WINS (UK), Women's Intervention Nutrition Study (UK).

* **Corresponding author:** D. B. Clarke, fax +44 1904 462111, email don.clarke@fera.gsi.gov.uk

In order to assess the impact of PE intake on health, a thorough understanding of the PE content of a wide range of foods present in the diet is required. In practice, assessing the impact can be achieved either by replacement of diet⁽¹⁵⁾, dietary supplementation⁽¹⁶⁾, direct analysis of duplicate diets⁽¹⁷⁾, or indirectly through total diet studies⁽¹⁸⁾, FFQ⁽¹⁹⁾ and food compositional databases⁽²⁰⁾. Compositional databases require the prior analysis of all items of food consumed by a given population and often must contain many thousands of entries⁽²¹⁾. Further, Internet-based resources offer a wider availability to food composition data⁽²²⁾. Once a database is fully populated and its use validated against a direct analysis method, then indirect dietary intake estimation, by FFQ, is relatively inexpensive.

Several databases have been constructed containing the PE content of foods and beverages. Some have focused on selected isoflavones⁽²³⁾, while others have included both isoflavones and lignans^(22,24–27). An inventory of PE databases has been published, with the guidance on the selection of best-suited databases and recommendations on their suitability⁽¹⁷⁾. Estimation of PE intake in Western countries has historically been biased towards underestimations by the inadequacy of coverage of key local foods and the increasing prevalence of soya ingredients in the production of frequently consumed processed foods which are not generally recognised as PE sources. Serum PE measurement is well known to be a poor index of long-term PE intake, while 24 h urinary PE excretion estimates perform much better and are considered to be more reliable⁽²⁸⁾.

Method

Recruitment and experimental design

Between January 2000 and November 2005, a dietary change feasibility study, The Women's Intervention Nutrition Study (UK) (WINS (UK) – stage 1), recruited postmenopausal women previously treated for breast cancer. A set of two hundred and sixty-one 4 d food and drink diaries and sixteen 7 d weighed intake diaries were collected as part of the preliminary screening for eligibility for WINS (UK) – stage 1, and it was noted that subjects reported some soya-rich products in their diets. These diaries were available for re-analysis⁽²⁹⁾. All women who had completed the WINS (UK) – stage 1 baseline screening diaries were contacted to ask for their consent to re-analyse their diaries in order to describe PE consumption patterns for this newly funded study. To allow 24 h urinalysis of PE urinary metabolites and comparisons with dietary intake estimations, fifty-five additional subjects were recruited to the PE study using the original WINS (UK) – stage 1 criteria, and summary data on screening, recruitment and participation for the PE study were compiled according to the Consolidated Standards of Reporting Trials guidance⁽³⁰⁾. The criteria for eligibility were as follows: postmenopausal and aged 48–78 years at diagnosis with breast cancer, histologically confirmed stage I, II or IIIa breast cancer, not participating in any conflicting studies, not following a special therapeutic diet, no past history of eating disorders, able to speak, read and write English and being geographically accessible for follow-up.

24 h urine collection and urinalysis

Of the fifty-five eligible subjects, fifty-four complied with the urine collection methodology which used 3-litre containers with ascorbic acid as a preservative and PABAcheck tablets (*para*-aminobenzoic acid (PABA); Laboratories for Applied Biology Limited), according to a standard community-based 24 h urine collection protocol. The subjects took one 80 mg tablet with each of the three main meals eaten on the day of urine collection. PABA in urine was measured colorimetrically by absorbance at 540 nm, after alkaline hydrolysis and a diazo coupling reaction with nitrous acid⁽³¹⁾ to confirm the completeness of the urine collection. A quality-control sample was run in triplicate within each analytical run. The completeness of the urine collection was assessed in terms of the percentage excretion of the total dose (240 mg) of PABA.

Database

A bespoke version of Dietplan6 (version 6.20c7, 2006; Forestfield Software Limited UK) database was created from both published and primary analysis sources to estimate PE intake. Careful consideration was given to data quality, including its origin and applicability to human dietary intake. A data quality criteria and scoring system for published values in peer-reviewed literature was compiled and used to determine

Table 1. Data quality criteria and scoring system for published literature

Criteria	Score
(1) Data published in peer-reviewed articles or data of equivalent quality	1
(2) Use of analytical reagents or better	1
(3) Use of appropriate high-quality internal standards from recognised sources	1
(4) Use of isotopically labelled standards	1
(5) Clear description of sampling procedure (use of at least three samples)	1
(6) Use of appropriate treated glassware (derivatisation) within the method	1
(7) Clear description of extraction procedure	1
(8) Use of enzymatic or acidic hydrolysis (or measurement of both glucosides and aglycones)	1
(9) Use of HPLC with positive confirmation of peaks by other means (e.g. ESI–MS)	1
(10) Use of LC–MS with appropriate identification of peaks	1
(11) Evidence of baseline chromatographic separation of analytes	1
(12) Evidence of LOD and LOQ of method	1
(13) Clear details on the recovery of the analyte (ideally greater than 60%)	1
(14) Clear details on the calculation of results	1
(15) Clear presentation of results in terms of expression as aglycone or glucoside	1
(16) Clear presentation of results in terms of dry weight or wet weight	1
(17) Ability to quantify phyto-oestrogen content as aglycone equivalents	1
(18) Evidence of the usage of quality-control procedures during analysis	1
(19) Clear information on inter- and intra-assay variation	1
(20) Results in line with those derived by other analysts	1

ESI, electrospray ionisation; LOD, limit of detection; LOQ, limit of quantification.

Table 3. Urinary phyto-oestrogen (PE) excretion ($\mu\text{g/d}$)*

No.	PE intake from food ($\mu\text{g/d}$)	Volume (litres)	PABA†	Individual PE and metabolites ($\mu\text{g/d}$)												Total PE ($\mu\text{g/d}$)
				Gen and metab-olite		Daid and metabolites					Gly and metab-olite					
				Gen	DHG	Daid	DHD	3OH-D	Equ	ODMA	Gly	DmGly	Form	End	Enl	
1	15 162.4	2.82	103	<LOD‡	<LOD	90	<LOD	59	<LOD	31	<LOD	203	<LOD	68	1700	2151
2	14 184.6	2.60	94	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	52	<LOD	<LOD	486	538
3	21 756.6	1.97	88	<LOD	<LOD	92	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	324	416
4	12 428.9	1.42	94	33	30	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	112	1088	1263
5	22 101.7	1.48	95	32	<LOD	61	<LOD	<LOD	18	24	<LOD	<LOD	<LOD	56	1116	1307
6	16 835.2	2.71	97	<LOD	<LOD	371	<LOD	<LOD	27	<LOD	<LOD	<LOD	27	87	3339	3851
7	36 857.9	2.17	96	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	59	1758	1817
8	3738.2	1.26	83	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	40	<LOD	40
9	4547.1	2.67	98	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	77	77
10	8086.4	1.46	98	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
11	12 345.0	2.39	92	36	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	36
12	13 929.8	1.68	90	23	<LOD	463	<LOD	<LOD	<LOD	40	<LOD	<LOD	18	275	2304	3123
13	8343.2	2.63	102	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	203	2768	2971
14	12 597.3	2.38	94	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	274	2030	2304
15	21 428.8	3.17	109	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	95	95
16	7363.7	2.85	96	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
17	49 083.4	2.95	93	1991	121	7779	1027	56	41	1159	693	<LOD	<LOD	<LOD	<LOD	12 867
18	5115.6	2.60	102	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	333	458	791
19	71 971.0	1.84	106	<LOD	59	<LOD	322	<LOD	<LOD	103	<LOD	<LOD	<LOD	3365	9754	13 603
20	1944.2	2.80	104	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	532	532
21	10 141.1	1.95	93	5345	123	5850	289	<LOD	1361	177	396	<LOD	<LOD	<LOD	1244	14 785
22	33 575.6	3.14	81	3458	342	3141	1135	31	<LOD	339	<LOD	<LOD	<LOD	91	<LOD	8537
23	17 053.0	1.50	92	<LOD	<LOD	260	<LOD	<LOD	<LOD	53	<LOD	<LOD	<LOD	44	293	650
24	13 595.2	2.25	109	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	259	<LOD	259
25	49 094.0	1.50	112	2672	365	2231	822	<LOD	<LOD	95	18	<LOD	<LOD	135	2190	8528
26	27 534.9	2.70	97	<LOD	<LOD	<LOD	103	<LOD	27	<LOD	<LOD	57	<LOD	<LOD	378	565
27	22 339.8	3.75	89	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
28	15 017.1	2.90	103	249	<LOD	818	<LOD	<LOD	<LOD	128	<LOD	<LOD	<LOD	<LOD	452	1647
29	17 148.7	3.10	107	143	<LOD	78	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	221
30	8320.1	2.71	95	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	73	1463	1536
31	44 739.7	2.50	99	7555	178	6328	335	48	<LOD	258	50	<LOD	<LOD	<LOD	80	14 832
32	760.1	2.49	80	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	35	1467	1502
33	13 833.8	1.56	100	555	225	1097	448	<LOD	<LOD	37	87	<LOD	<LOD	<LOD	1296	3745
34	10 410.8	2.04	91	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD
35	1195.8	1.89	80	289	<LOD	818	<LOD	<LOD	<LOD	43	38	<LOD	<LOD	53	584	1825
36	6907.6	6.16	94	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	942	942
37	37 792.0	2.83	79	34	<LOD	464	<LOD	<LOD	42	45	<LOD	<LOD	<LOD	382	6523	7490
38	7192.4	3.15	99	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	<LOD	491	491
Mean	18 328.2	2.472	96	590	38	788	118	5	40	67	34	8	1	156	1190	3035
sd	15 617.5	0.866	8	1610	92	1869	285	16	220	197	128	35	5	545	1914	6916

D. B. Clarke *et al.*

Gen, genistein; Daid, daidzein; Gly, glycitein; PABA, *para*-aminobenzoic acid; DHG, dihydrogenistein; DHD, dihydrodaidzein; 3OH-D, 3-hydroxydaidzein; Equ, equol; ODMA, *O*-desmethyl angolensin; DMGly, desmethylglycitein; Form, formononetin; End, enterodiol; Enl, enterolactone; LOD, limit of detection.

* No coumestrol, biochanin A, 6-hydroxy-*O*-desmethylangolensin or 8-hydroxydaidzein was detected in any urine sample.

† Percentage recovery of 3 × 80 mg of PABA.

‡ Less than 10 $\mu\text{g/l}$

Bland–Altman plots were used to assess the relationship between estimated PE intakes using the 4 d diaries and urinary PE excretion results⁽³⁴⁾. Statistical analyses were conducted using SPSS (version 12, annex 6; SPSS, Inc.).

Results

The dietary analysis database created in the present study used a more critical evaluation of the published literature than has been the case for previous databases⁽²⁶⁾ and complies with the guidance on reporting clinical studies of soya intervention⁽³⁵⁾. The present study further benefited from the inclusion of the primary analysis of an additional thirty-four food and beverage items known to be consumed by the study population and for which PE content data were lacking. Considerable recoding of the food and beverage items listed in the diaries was required to allow the PE study data to be read alongside the macronutrient assessment data within each report from 551 separately coded foods (see the Supplementary material, available online). The process of recoding the food items was also indicated when the actual food or beverage was not explicitly listed within the database, but was deemed dietetically similar. For example, PE fraction data were available for fresh tomatoes. Giving due consideration to the fact that food processing and cooking generally reduce the PE content, through loss of water (dehydration) or boiling (aqueous extraction)⁽³⁶⁾, tinned tomatoes and grilled tomatoes were recoded accordingly, so as to represent their potential contribution to the intake of the respective PE fractions.

Recovery of 85–110% of the PABA dose from the urine is generally accepted as complete urine collection. Values of less than 70% indicate incomplete urine collection⁽³⁷⁾. There was a trend ($P < 0.1$) for the older women in the present study to excrete slightly less PABA in the 24 h urine collection. This is consistent with the literature, although the reduction in excretion is only small⁽³⁸⁾. Taking this into account, the cut-off was revised to $100 \pm 22\%$ recovery of the PABA dose; thirty-eight of the fifty-four urine collections were thus deemed adequate, with an average recovery of 95 (SD 8)%.

The urinalysis results are shown in Table 3. Biochanin A, 8-hydroxydaidzein and coumestrol were not detected in any samples and have, therefore, been excluded from the data table. The mean total PE excretion was 3.0 (SD 6.9) mg/d ($n = 38$, < 0.01 –15 mg/d).

Of the fifty-four women (15%) who provided a 24 h urine collection, eight were found to be Equ producers, based on the detection of more than $10 \mu\text{g/l}$ (41.3 nmol/l) of Equ. Of these eight women, two (4%) excreted Equ at levels greater than 1000 nmol/d (4198 and 5618 nmol Equ/d) and could be described as good Equ producers on this basis. The remaining six excreted 74–173 nmol Equ/d and were, therefore, poor Equ producers. Of the six Equ producers, five provided complete urine samples, as confirmed by PABA analysis, hence one of the high Equ producers was excluded from subsequent analysis. Setchell & Cole⁽³⁹⁾ has designated a formula based on a nmol/l urinary \log_{10} Equ: Daid ratio of > -1.75 as indicating Equ production, with expected distributions of 25% in

non-vegetarian adults and 59% in vegetarian adults after a Daid challenge. This is a more intuitive approach that can better predict which subjects would be high Equ excretors given a suitable Daid challenge. Of the fifty-four subjects, twenty-two had detectable urinary Daid or Equ levels; it was necessary to enter a non-zero value ($0.05 \mu\text{g/l}$) in place of $< \text{limit of detection}$ ($10 \mu\text{g/l}$) in order to use the formula. It can clearly be seen that seven (15%) of the fifty-four were then classified as Equ producers (Fig. 1). As many subjects had excreted neither Equ nor Daid, this dataset only supports the hypothesis that 25% of subjects are Equ producers in contrast to those (seven (32%) out of twenty-two) whose urine contained isoflavones.

The Spearman's correlation coefficients measured in the present study (Tables 4 and 5) are virtually identical to the best recent examples⁽¹⁹⁾, with recent diet to urine values of 0.54 (isoflavones and total PE) and 0.40 (lignans) and urinary to FFQ correlations for total isoflavones (Daid, genistein and Equ) of 0.57 (95% CI), increasing to 0.72 for the 24 h recall⁽⁴⁰⁾. Literature correlations reflecting the reproducibility of the FFQ of 0.67–0.81 and validity correlations (FFQ compared with dietary) of 0.67–0.79 with urinary validity correlations of 0.41–0.51 (isoflavones) and 0.16–0.21 (lignans) are reported⁽²⁵⁾.

Discussion

The volume of collected urine was 2.52 (SD 0.88) litres ($n = 54$, 1.26–6.16 litres) and, while this was considerably higher than volumes measured in similar studies, it was largely unchanged




Fig. 1. Comparison of equol production status by (a) concentration and (b) \log_{10} transformation of the metabolite:precursor ratios. \blacklozenge , Daidzein; \blacksquare , equol. (A colour version of this figure can be found online at <http://www.journals.cambridge.org/bjcn>).

Table 4. Spearman's correlations between phyto-oestrogen (PE) intake ($\mu\text{g}/1000\text{kcal}/\text{d}$) measured using 4 d diaries and 7 d weighed intake data

Dietary PE	Spearman's ρ
Daidzein	0.723**
Genistein	0.763**
Glycitein	0.714**
Formononetin	-0.070
Biochanin A	0.225
Coumestrol	0.563*
Matairesinol	0.622*
Secoisolariciresinol	0.640*
Total PE	0.749**

* $P < 0.05$ ** $P < 0.1$.

by the elimination of the incomplete collections (2.47 (SD 0.87) litres; n 38, 1.26–6.16 litres). This indicates that low collection volume was not the major factor in the low completion rate.

The urinalysis results and 7 d weighed intakes contributed to the validation of the 4 d food and drink diary as a data collection tool. Variations between subjects in terms of absorption, distribution, metabolism and excretion of PE fractions and their excretion products are an important consideration when interpreting PE urinalysis results overall. While an attempt to control for such inter-individual variations could be made by comparing averaged dietary intake over 4 d with the urinalysis results, it would not be possible to individually predict the rate at which PE fractions and their excretion products would appear in urine. This may warrant attempts to collect urine over a longer period in future studies.

Data on PE intake in other study populations have been reported in the literature^(4,41–47). A direct comparison of quantified intakes is difficult as some researchers have reported intakes of a limited number of individual PE and the dietary analysis database used to quantify intake is not always explicit.

Table 5. Spearman's correlations between estimated dietary and measured urinary phyto-oestrogen (PE) values

Dietary PE ($\mu\text{g}/\text{d}$)	Urinary PE and metabolite ($\mu\text{g}/\text{l}$)	Spearman's ρ
Daidzein	Daidzein	0.517**
Daidzein	Dihydrodaidzein	0.398**
Daidzein	3-Hydroxydaidzein	0.403**
Daidzein	O-DMA	0.534**
Daidzein	6-OH-O-DMA	0.267
Daidzein	Equol	-0.147
Daidzein	Daidzein and metabolites†	0.492**
Genistein	Genistein	0.507**
Genistein	Dihydrogenistein	0.468**
Glycitein	Glycitein	0.441**
Glycitein	Desmethylglycitein	-0.021
Matairesinol	Enterodiol	0.079
Matairesinol	Enterolactone	0.088
Secoisolariciresinol	Enterodiol	0.287
Secoisolariciresinol	Enterolactone	0.221
Matairesinol + secoisolariciresinol	Enterodiol + enterolactone	0.238
Total PE	Total phyto-oestrogens	0.450**

** $P < 0.1$.

† Daidzein and metabolites = daidzein, dihydrodaidzein, 3-hydroxydaidzein, O-desmethyldaidzein (O-DMA) and 6-hydroxy-O-DMA.

There is considerable methodological variation between these studies. In particular, the derivation of the dietary analysis database used in each study is not always clear. Given that such variation introduces error, a quantitative comparison between study populations is difficult to achieve. While it is beyond the scope of the present study to conduct any statistical comparisons between the study populations described by other researchers and the present results, a review of the published data does reinforce the need to ensure that a comprehensive and quality-assured dietary analysis database is used in such studies. The need to comprehensively analyse foodstuffs for more than just their isoflavone PE content is also evident. In general, the British are low consumers of soya⁽⁴⁸⁾ and the contribution of low-isoflavone foodstuffs is potentially under-represented in existing dietary analysis databases.

Thus, assessing intake and exposure should consider other PE fraction sources with known biological activity. A high intake of dietary lignans, for example, has been associated with a reduced risk of breast cancer in a large cohort study of French women, a population that does not consume a diet rich in soya products⁽⁴⁹⁾. The techniques for quantifying lignan intake are not comprehensively described and the quality of the database used to analyse intake warrants review. However, these findings suggest an emerging role for dietary lignans with respect to breast cancer.

The interpretation of correlations with the urinalysis results is complicated by the known inter-individual variations in the enterohepatic circulation and the efficiency of microbial conversion of PE into other bioactive oestrogenic metabolites in the gut. Identifying 'equol producers' is important, however, in the assessment of exposure to PE, particularly in a potentially hyper-exposed subgroup of the population such as women who have been treated for breast cancer.

Conclusion

The present study provide a unique opportunity to create a bespoke dietary analysis database to measure PE consumption. It was informed by the dietary consumption patterns of women who had previously been treated for postmenopausal breast cancer and who were, as such, potential high consumers of PE compared with the general population. Quantifying true dietary intake is always challenging as the very attempts to measure it can alter actual and reported consumption. However, when validated methods for recording dietary intake are used, the methods to quantify intake rely upon a comprehensive nutrient database so that consumption can be meaningfully assessed.

Women who have been treated for breast cancer are likely to have different PE intakes which reflect differences in individual food preferences and, quite possibly, variations in the women's existing knowledge of PE themselves. The availability of a comprehensive database for reliably measuring PE intake is a valuable resource for researchers and healthcare professionals who wish to measure intake and discuss in detail the contribution of these bioactive compounds to the health of the population.

Supplementary material

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/S0007114512004394>

Acknowledgements

This study was funded under the UK Food Standards Agency (FSA) project code T05030. Financial support was provided by the UK FSA under contract T05030, and this support is gratefully acknowledged. The conclusions and opinions expressed are the views of the authors alone. The project had external ethical approval, provided by the Southampton and South-West Research Ethics Committee (B). The study subjects provided written consent to being involved in the study. All authors made a significant contribution to this manuscript. B. M. P. was the principal investigator. B. M. P., R. M. R., J. M. L. and M. R. derived the study concept. J. E. B., D. B. C., A. S. L. and D. J. C. assisted in and proposed the study design. B. M. P., J. M. L., J. E. B. and L. S. conducted the data acquisition. D. B. C., A. S. L. and V. A. B.-H. conducted the PE analysis. J. M. L., B. M. P., D. J. C., R. M. R., J. E. B., L. S., M. R. and D. B. C. interpreted the data. J. M. L., B. M. P. and D. J. C. performed the statistical analysis. D. B. C., B. M. P. and J. M. L. prepared the manuscript and all authors edited the paper. The authors declare that there are no conflicts of interest.

References

1. Tham DM, Gardner CD & Haskell WL (1998) Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological and mechanistic evidence. *J Clin Endocrin Met* **83**, 2223–2235.
2. Geller SE & Studee L (2005) Botanical and dietary supplements for menopausal symptoms: what works, what doesn't. *J Wom Health (Larchmt)* **14**, 634–649.
3. Chiechi LM & Micheli L (2005) Utility of dietary phytoestrogens in preventing postmenopausal osteoporosis. *Curr Top Nutra Res* **3**, 15–28.
4. Cotterchio M, Boucher BA, Manno M, *et al.* (2006) Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. *J Nutr* **136**, 3046–3053.
5. Trock BL, Hilakivi-Clarke L & Clarke R (2006) Meta-analysis of soy intake and breast cancer risk. *J Natl Cancer Inst* **98**, 459–471.
6. Wu AH, Yu NC, Tseng CC, *et al.* (2008) Epidemiology of soy exposures and breast cancer risk. *Br J Cancer* **98**, 9–14.
7. Gammon MD, Fink BN, Steck SE, *et al.* (2008) Soy intake and breast cancer: an elucidation of an unanswered question. *Br J Cancer* **98**, 2–3.
8. Messina M & Wu AH (2009) Perspectives on the soy–breast cancer relation. *Am J Clin Nutr* **89**, 1673S–1679S.
9. Velentzis LS, Cantwell MM, Cardwell C, *et al.* (2009) Lignans and breast cancer risk in pre- and post-menopausal women: meta-analysis of observational studies. *Br J Cancer* **100**, 1492–1498.
10. Patisaul HB & Jefferson W (2010) The pros and cons of phytoestrogens. *Front Neuroendocrinol* **31**, 400–419.
11. Gold EB, Flatt SW, Pierce JP, *et al.* (2006) Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study. *Menopause* **13**, 423–433.
12. Kurzer MS (2003) Phytoestrogen supplement use by women. *J Nutr* **133**, 1983S–1986S.
13. Rice S & Whitehead SA (2006) Phytoestrogens and breast cancer – promoters or protectors? *Endocr Relat Cancer* **13**, 995–1015.
14. Committee on Toxicology of Chemicals in Food, Consumer Products and the Environment (2003) *Phytoestrogens and Health*, London: Food Standards Agency.
15. Wiseman H, Casey K, Clarke D, *et al.* (2002) Isoflavone aglycone and gluco-conjugate content of commercial and “home-prepared” high soy and low soy foods and food dishes in the UK selected for use in chronic controlled nutritional studies. *J Agric Food Chem* **50**, 1404–1419.
16. Clarke DB, Bailey V & Lloyd AS (2008) Determination of phytoestrogens in dietary supplements by LC–MS/MS. *Food Add Contam* **25**, 534–547.
17. Clarke DB, Barnes KA, Castle L, *et al.* (2003) Levels of phytoestrogens, inorganic trace-elements, natural toxicants and nitrate in vegetarian duplicate diets. *Food Chem* **81**, 287–300.
18. Clarke DB & Lloyd AS (2004) Dietary exposure estimates of isoflavones from the 1998 UK Total Diet Study. *Food Add Contam* **21**, 305–316.
19. French MR, Thompson LU & Hawker GA (2007) Validation of a phytoestrogen food frequency questionnaire with urinary concentrations of isoflavones and lignan metabolites in premenopausal women. *J Am Coll Nutr* **26**, 76–83.
20. Schwartz H, Sontang G & Plumb J (2009) Inventory of phytoestrogen databases. *Food Chem* **113**, 736–747.
21. Ritchie MR, Cummings JH, Morton MS, *et al.* (2006) A newly constructed and validated isoflavone database for the assessment of total genistein and daidzein intake. *Br J Clin Nutr* **95**, 204–213.
22. USDA (2008) Database for the isoflavone content of selected foods Release 2.0. <http://www.ars.usda.gov/Services/docs.htm?docid=6382> (accessed 27 May 2010).
23. Ritchie MR, Morton MS, Deighton N, *et al.* (2004) Plasma and urinary phytoestrogens as biomarkers of intake: validation by duplicate diet analysis. *Br J Nutr* **91**, 447–457.
24. Pillow PC, Duphorne CM, Chang S, *et al.* (1999) Development of a database for assessing dietary phytoestrogen intake. *Nutr Cancer* **33**, 3–19.
25. Horn-Ross PL, Barnes S, Lee VS, *et al.* (2006) Reliability and validity of an assessment of usual phytoestrogen consumption (United States). *Cancer Causes and Control* **17**, 85–93.
26. Kiely M, Faughnan M, Wahala K, *et al.* (2003) Phytoestrogen levels in foods: the design and construction of the VENUS database. *B J Nutr* **89**, S19–S23.
27. Blitz CL, Murphy SP & Au DLM (2007) Adding lignan values to a food composition database. *J Food Comp Anal* **20**, 99–105.
28. Fraser GE, Franke AA, Jaceldo-Siegl K, *et al.* (2010) Reliability of serum and urinary isoflavones estimates. *Biomarkers* **15**, 135–139.
29. Parry BM, Milne JM, Yadegarfar G, *et al.* (2011) Dramatic dietary fat reduction is feasible in postmenopausal breast cancer patients: results of the randomised study, WINS(UK) – Stage 1. *Eur J Surg Oncol* **37**, 848–855.
30. Moher D, Schulz KF & Altman D (2001) The CONSORT statement: revised recommendations for improving the quality of reports for parallel-group randomised trials. *JAMA* **285**, 1987–1991.
31. Bingham S & Cummings JH (1983) The use of 4-amino benzoic acid as a marker to validate the completeness of 24 h collections in man. *Clin Sci* **64**, 629–635.

32. Food Standards Agency (2002) *McCance and Widdowson's The Composition of Foods*, 6th summary ed. Cambridge: Royal Society of Chemistry.
33. Clarke DB, Lloyd AS, Botting NP, *et al.* (2002) Measurement of intact sulfate and glucuronide phytoestrogen conjugates in human urine using isotope dilution liquid chromatography–tandem mass spectrometry with [¹³C₃]-isoflavone internal standards. *Anal Biochem* **309**, 158–172.
34. Bland JM & Altman DG (1986) Statistical method for assessing agreement between two methods of clinical measurement. *Lancet* **i**, 307–310.
35. Klein MA, Nahin RL, Messina MJ, *et al.* (2010) Guidance from an NIH workshop on designing, implementing and reporting clinical studies of soy intervention. *J Nutr* **140**, 1192S–1204S.
36. Liggins J, Bluck IJC, Runswick S, *et al.* (2000) Daidzein and genistein content of vegetables. *Br J Nutr* **84**, 717–725.
37. Neuhauser ML, Tinker L, Shaw PA, *et al.* (2008) Use of recovery markers to calibrate nutrient consumption self-reports in the women's health initiative. *Am J Epidemiol* **167**, 1247–1259.
38. Jakobsen J, Pedersen AN & Ovesen L (2003) *Para*-amino benzoic acid (PABA) used as a marker for completeness of 24 h urine: effects of age and dosing schedule. *Eur J Clin Nutr* **57**, 138–142.
39. Setchell KDR & Cole SJ (2006) Method for defining equal-producer status and its frequency among vegetarians. *J Nutr* **136**, 2188–2193.
40. Jaceldo-Siegl K, Fraser GE, Chan J, *et al.* (2008) Validation of soy protein estimates from a food-frequency questionnaire with repeated 24-h recalls and isoflavonoid excretion in overnight urine in a Western population with a range of soy intakes. *Am J Clin Nutr* **87**, 1422–1427.
41. de Kleijn MJJ, van der Schouw YT, Wilson PWF, *et al.* (2002) Dietary intake of phytoestrogens is associated with a favourable cardiovascular risk profile in postmenopausal US women – the Framingham Study. *J Nutr* **132**, 276–282.
42. Keinan-Boker L, van der Schouw YT, De Kleijn MJJ, *et al.* (2002) Intake of dietary phytoestrogens by Dutch women. *J Nutr* **132**, 1319–1328.
43. Horn-Ross PL, John EM, Canchola AJ, *et al.* (2003) Phytoestrogen intake and endometrial cancer risk. *J Natl Cancer Inst* **95**, 1158–1164.
44. Vrieling A, Voskuil DW, Sas Bueno des Mesquita H, *et al.* (2004) Dietary determinants of circulating insulin-like growth factor (IGF)-1 and IGF binding proteins 1, -2 and -3 in women in the Netherlands. *Cancer Causes and Control* **15**, 787–796.
45. Bhakta D, dos Santos Silva I, Higgins C, *et al.* (2005) A semi-quantitative food frequency questionnaire is a valid indicator of the usual intake of phytoestrogens by South Asian women in the UK relative to multiple 24-hour recalls and multiple plasma samples. *J Nutr* **135**, 116–123.
46. Cheung EYN, Ho AYY, Lam KF, *et al.* (2005) Determinants of bone mineral density in Chinese men. *Osteoporos Int* **16**, 1481–1486.
47. Hedelin M, Klint A, Chang ET, *et al.* (2006) Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the Cancer Prostate Sweden Study (Sweden). *Cancer Causes and Control* **17**, 169–180.
48. Department for Environment, Food and Rural Affairs (2007) *UK Purchases and Expenditure on Food and Drink and Derived Energy and Nutrient Intakes in 2005–06*, published 18 January 2007, a National Statistics publication. London: Defra.
49. Touillaud MS, Thiebaut ACM, Fournier A, *et al.* (2007) Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. *J Nat Cancer Inst* **99**, 475–486.